| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | ALKS Alkermes Plc | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2,034 | $54.03 | $109,897.02 | -0.9% | - | - | |
| Jul 2, 2026 | ANIP Ani Pharmaceuticals, Inc. | Carey Stephen P.55 | SVP &CFO | Sell | 3,313 | $86.00 | $284,918.00 | -1.8% | - | - | |
| Jun 29, 2026 | NBIX Neurocrine Biosciences, Inc. | Lippoldt Darin60 | Chief Legal Officer | Sell | 10,000 | $170.15 | $1,701,492.09 | -5.7% | - | - | |
| Jun 26, 2026 | TCNNF Trulieve Cannabis Corp. | Rivers Kim A. | Chairman And CEO | Sell | 136,811 | $8.76 | $1,197,917.12 | -8.5% | - | - | |
| Jun 25, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $550.40 | $5,228,772.56 | -1.9% | - | - | |
| Jun 25, 2026 | TCNNF Trulieve Cannabis Corp. | Rivers Kim A. | Chairman And CEO | Sell | 1,080,000 | $8.27 | $8,936,520.00 | -15.6% | - | - | |
| Jun 23, 2026 | AQST Aquestive Therapeutics, Inc. | Krop Julie | Director | Sell | 25,000 | $5.02 | $125,392.50 | -100% | - | - | |
| Jun 23, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $543.95 | $5,167,570.77 | -2.9% | - | - | |
| Jun 22, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $537.74 | $5,108,527.04 | -2.9% | - | - | |
| Jun 22, 2026 | LQDA Liquidia Corporation | Bloch Stephen M | Director | Sell | 100,000 | $75.74 | $7,573,703.95 | -5.3% | - | - | |
| Jun 17, 2026 | ETON Eton Pharmaceuticals, Inc. | Adams Jennifer McKie | Director | Sell | 50,000 | $32.48 | $1,623,795.00 | -100% | - | - | |
| Jun 17, 2026 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Operating Officer | Sell | 14,027 | $31.50 | $441,850.50 | -3.1% | - | - | |
| Jun 17, 2026 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 12,063 | $30.72 | $370,518.25 | -40.0% | - | - | |
| Jun 17, 2026 | HIMS Hims & Hers Health, Inc. | Elshenawy Mohamed | CTO | Sell | 30,040 | $31.50 | $946,260.00 | -22.9% | - | - | |
| Jun 16, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $549.80 | $5,223,068.48 | -2.1% | - | - | |
| Jun 16, 2026 | IRWD Ironwood Pharmaceuticals, Inc. | McHugh Julie53 | Director | Sell | 21,571 | $3.73 | $80,459.83 | -7.9% | - | - | |
| Jun 15, 2026 | JUSHF Jushi Holdings Inc. | Mosier Michelle O | Chief Financial Officer | Buy | 25,500 | $0.49 | $12,485.90 | +6.9% | - | - | |
| Jun 12, 2026 | ALKS Alkermes Plc | Wright Christopher I | Director | Sell | 2,000 | $45.10 | $90,200.00 | -7.2% | - | - | |
| Jun 11, 2026 | PCRX Pacira Biosciences, Inc. | Riker Lauren76 | Senior Vice President, Finance | Sell | 6,115 | $23.50 | $143,702.50 | -8.9% | - | - | |
| Jun 9, 2026 | PFE Pfizer Inc. | Damico Jennifer B.58 | SVP &Controller | Sell | 2,000 | $25.70 | $51,400.00 | -6.0% | - | - | |
| Jun 8, 2026 | UTHR United Therapeutics Corporation | Edgemond James | CFO And Treasurer | Sell | 10,000 | $547.50 | $5,475,044.88 | -5.4% | - | - | |
| Jun 8, 2026 | ANIP Ani Pharmaceuticals, Inc. | Haughey Thomas | Director | Sell | 2,000 | $80.88 | $161,760.00 | -4.9% | - | - | |
| Jun 8, 2026 | INM Inmed Pharmaceuticals Inc. | Vivo Opportunity, LLC67 | 10% Owner | Buy | 249,227 | $1.57 | $391,554.51 | +4.2% | - | - | |
| Jun 4, 2026 | NBIX Neurocrine Biosciences, Inc. | Norwalk Leslie V64 | Director | Sell | 1,250 | $168.06 | $210,071.63 | -30.6% | - | - | |
| Jun 4, 2026 | PCRX Pacira Biosciences, Inc. | Williams Kristen76 | Chief Administrative Officer | Sell | 10,259 | $22.27 | $228,467.93 | -5.8% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.